Q BioMed Inc. QBIO
0.00 USD 0.00 (+0.00%)
Apr 2, 2026, 9:30 AM EDT
0.0001 Day range 0.0001
0.0001 52-week range 0.02505
- YTD
- -0.00%
- 1 year
- -50.00%
- Market cap
- 14.51K
- EPS (ttm)
- -0.02
- P/E ratio
- -0.01
- YTD return
- -0.00%
- 1-year return
- -50.00%
- Volume
- 5.70K
- Avg volume
- 376
- Open
- 0.0001
- Previous close
- 0.0001
- Day's range
- 0.0001 – 0.0001
- 52-week range
- 0.0001 – 0.02505
- Earnings date
- May 26, 2023
No chart data for this range yet.
Next earnings
May 26, 2023
Expected May 26, 2023. Consensus EPS estimate 0.00.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Jun 16, 2023 | Feb 1, 2023 | 0.00 | -0.02 | — | — |
| May 26, 2023 | Nov 1, 2022 | 0.00 | — | — | — |
| Nov 3, 2022 | Aug 1, 2022 | 0.00 | -0.03 | — | — |
News
Q Biomed (OTCMKTS:QBIO) vs. GeneDx (NASDAQ:WGS) Financial Comparison 
Establishment Labs (NASDAQ:ESTA) & Q Biomed (OTCMKTS:QBIO) Critical Contrast 
Q Biomed (OTCMKTS:QBIO) & Auna (NYSE:AUNA) Head to Head Review 
Q Biomed (OTCMKTS:QBIO) & GoodRx (NASDAQ:GDRX) Financial Survey 
SBC Medical Group (NASDAQ:SBC) and Q Biomed (OTCMKTS:QBIO) Head-To-Head Contrast 
Q BioMed receives US patent and notice of allowance in Europe for Uttroside B; seeks ways to boost shareholder value 
Q BioMed gets notice of allowable US patent for liver cancer treatment Uttroside B 
Q BioMed boosted by multi-million dollar asset as it converts long-term royalty into equity stake in Mannin Research 
Q Biomed announces patent for groundbreaking GDF15 biomarker for glaucoma detection and treatment 
Q BioMed reports Strontium89 sales revenue surge in shareholder update
Your note
Sign in to keep a note on QBIO — it syncs with the Stock Master app.